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Prediction of risk of death and myocardial infarction in
the six months after presentation with acute coronary
syndrome: prospective multinational observational study
(GRACE)
Keith A A Fox, Omar H Dabbous, Robert J Goldberg, Karen S Pieper, Kim A Eagle,
Frans Van de Werf, Álvaro Avezum, Shaun G Goodman, Marcus D Flather, Frederick A Anderson Jr,
Christopher B Granger, for the GRACE Investigators
Abstract
Objective To develop a clinical risk prediction tool for
estimating the cumulative six month risk of death and
death or myocardial infarction to facilitate triage and
management of patients with acute coronary
syndrome.
Design Prospective multinational observational study
in which we used multivariable regression to develop
a final predictive model, with prospective and external
validation.
Setting Ninety four hospitals in 14 countries in
Europe, North and South America, Australia, and
New Zealand.
Population 43 810 patients (21 688 derivation set;
22 122 in validation set) presenting with acute
coronary syndrome with or without ST segment
elevation enrolled in the global registry of acute
coronary events (GRACE) study between April 1999
and September 2005.
Main outcome measures Death and myocardial
infarction.
Results 1989 patients died in hospital, 1466 died
between discharge and six month follow-up, and 2793
sustained a new non-fatal myocardial infarction. Nine
factors independently predicted death and the
combined end point of death or myocardial infarction
in the period from admission to six months after
discharge: age, development (or history) of heart
failure, peripheral vascular disease, systolic blood
pressure, Killip class, initial serum creatinine
concentration, elevated initial cardiac markers, cardiac
arrest on admission, and ST segment deviation. The
simplified model was robust, with prospectively
validated C-statistics of 0.81 for predicting death and
0.73 for death or myocardial infarction from
admission to six months after discharge. The external
applicability of the model was validated in the dataset
from GUSTO IIb (global use of strategies to open
occluded coronary arteries).
Conclusions This risk prediction tool uses readily
identifiable variables to provide robust prediction of
the cumulative six month risk of death or myocardial
infarction. It is a rapid and widely applicable method
for assessing cardiovascular risk to complement
clinical assessment and can guide patient triage and
management across the spectrum of patients with
acute coronary syndrome.
Introduction
Patients with acute coronary syndrome present with
diverse clinical, electrocardiographic, and enzyme or
marker characteristics and experience a wide range of
serious cardiovascular outcomes.1 2 Estimated risk,
based on clinical characteristics, is challenging and
imprecise, yet risk assessment is needed to guide triage
and key management decisions.
The large multinational observational global regis-
try of acute coronary events (GRACE) has been used
to derive regression models to predict death in hospi-
tal3 and death after discharge4 in patients with acute
coronary syndrome. However, a comprehensive risk
model is required to predict the cumulative risk of
death and death or myocardial infarction during the
high risk first six months after initial presentation with
acute coronary syndrome, the period when most com-
plications occur. Because triage and management
decisions are required within the first hours or days
after initial presentation, we derived a risk tool from
characteristics of patients with acute coronary syn-
drome at initial presentation.
Methods
GRACE methods and design
Full details of the GRACE registry have been
published elsewhere.5 6 It was designed to reflect an
This is the abridged version of an article that was posted on
bmj.com on 10 October 2006: http://bmj.com/cgi/doi/10.1136/
bmj.38985.646481.55
Full details of inclusion criteria and standard definitions can be
found on bmj.com.
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unbiased population of patients with acute coronary
syndrome in 94 hospitals in 14 countries. All cases
were assigned to one of the following categories: ST
segment elevation myocardial infarction, non-ST
elevation myocardial infarction, or unstable angina
(see bmj.com for details).
Statistical methods
We used two primary end points: all cause death or the
composite measure of death or non-fatal myocardial
infarction during admission to hospital or after
discharge (presentation to six months).
We have summarised the distributions of continu-
ous variables with medians and 25th and 75th centiles
and reported the categorical variables as frequencies
and percentages. Events that occurred after six months
were censored. See bmj.com for variables included in
the analysis from hospital admission to six month
follow-up. We used a Cox regression model to
compute crude hazard ratios and 95% confidence
intervals to examine the individual relation between
each predictor and death and death or myocardial inf-
arction during follow-up (0 to 6 months).
We entered all demographic and clinical variables
identified by the crude regression analysis into the step-
wise multiple Cox regression (backward) analysis to pro-
duce final models for predicting death and death or
myocardial infarction. The discriminative power of the
final models was assessed by the mean of the area under
the receiver operating characteristic (ROC) curve
(C-statistic). The model was tested prospectively in a
separate dataset in GRACE (n = 22 122) and also in an
independent external dataset, the GUSTO IIb (global
use of strategies to open occluded coronary arteries IIb)
dataset, comprising the entire spectrum of patients with
acute coronary syndrome (12 142 patients, 4131 with
ST elevation myocardial infarction, 8011 with non-ST
elevation myocardial infarction) (see bmj.com).
Results
Study population
The derivation population comprised 26 267 patients
with suspected acute coronary syndrome enrolled
between 1 April 1999 and 30 September 2002. After
exclusions the study population comprised 21 688
patients of whom 19 931 were alive at six month
follow-up.
A total of 1757 (9.1%) deaths occurred, 1046 in hos-
pital (4.9% (1046/21 573) among patients with a
diagnosis of acute coronary syndrome on admission)
and 711 during the period after discharge (4.9%
(711/15 265). We had no information on mortality (in
hospital or after discharge) for 51 patients. In the deriva-
tion set, 3110 (15.8%) patients died (n = 1757) or experi-
enced a non-fatal myocardial infarction (n = 1353)
between presentation and six month follow-up.
Early risks were highest for patients with ST
segment elevation myocardial infarction but by six
months the risk of death was similar to those with
non-ST segment elevation myocardial infarction (fig1).
Of those who survived to six months after discharge,
36.2% (258/711) presented with ST segment elevation
myocardial infarction compared with 50.0% (880/
1757) of those who died during admission or
follow-up. Raised cardiac markers were detected in
35.0% (6883/19 688) of those who survived compared
with 53.2% (905/1701) of those who died.
Validation population
The validation set comprised 22 122 patients enrolled
in this multinational registry between 1 October 2003
and 30 September 2005. A total of 1730 (9.0%)
patients died between hospital admission and six
month follow-up, 948 in hospital (4.3% among patients
with an admission diagnosis of acute coronary
syndrome) and 782 (5.4%) after discharge. No
information on mortality was available for 38 patients.
In total, 2720 patients died (n = 1730) or experienced a
non-fatal myocardial infarction (n = 990) between
presentation and six month follow-up.
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Fig 1 Risk of death from admission to hospital to six months after
discharge (patients separated into unstable angina, non-ST segment
elevation myocardial infarction, and ST segment elevation myocardial
infarction)
Table 1 Final risk models predicting death and death or myocardial infarction from
hospital admission to six month follow-up (hazard ratios and 95% confidence intervals)
Predictors 2 Death model 2 Death/MI model
Age (per 10 year increase) 505.7 1.8 (1.68 to 1.84) 176.3 1.25 (1.21 to 1.29)
Medical history:
Congestive heart failure 34.2 1.5 (1.32 to 1.73) 22.1 1.3 (1.17 to 1.45)
Hypertension 8.8 1.2 (1.05 to 1.33) —
Peripheral vascular disease 21.8 1.4 (1.21 to 1.62) 10.5 1.2 (1.08 to 1.36)
PCI 8.3 0.8 (0.64 to 0.93) —
Presentation characteristics:
Pulse (per 30 beats/min increase) 44.3 1.2 (1.16 to 1.31) —
Systolic blood pressure (per 20
mm Hg decrease)
152.0 1.2 (1.22 to 1.30) 52.9 1.1 (1.07 to 1.13)
Killip class7 (per level increase) 142.8 1.5 (1.41 to 1.62) 126.2 1.4 (1.30 to 1.46)
Initial serum creatinine (per 88
mol/l* increase)
135.3 1.2 (1.19 to 1.29) 41.1 1.1 (1.08 to 1.16)
Initial cardiac markers or enzymes 63.0 1.6 (1.42 to 1.78) 184.3 1.7 (1.60 to 1.87)
Cardiac arrest 58.5 2.6 (2.00 to 3.32) 55.4 2.2 (1.76 to 2.63)
Findings on electrocardiography:
ST segment deviation 46.8 1.6 (1.41 to 1.88) —
Left bundle block branch 10.0 1.3 (1.10 to 1.60) —
No of leads with ST segment
elevation or depression
20.1 1.2 (1.10 to 1.33) 158.4 1.4 (1.34 to 1.49)
ST depression, anterior — 36.2 1.3 (1.22 to 1.47)
ST depression, inferior — 10.8 1.2 (1.09 to 1.40)
Other changes — 7.2 1.1 (1.04 to 1.27)
Hosmer and Lemeshow goodness of
fit test
0.30 0.42
C-statistic 0.82 0.70
PCI=percutaneous coronary intervention.
**Equivalent to 1 mg/dl.
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Predictors of mortality
From admission to six month follow-up, Killip class7
and advanced age were the most powerful predictors
of death in the univariable analysis.
After multivariable analysis, the highest hazard
ratios for death were cardiac arrest on admission and
increasing age. These two key prognostic factors were
closely followed by raised cardiac markers or enzyme
activity and ST segment deviation (table 1).
Risk models predicting death and death or
myocardial infarction
The risk model comprises 14 predictors of death and
12 predictors of death or myocardial infarction. The
predictive accuracy of the model was good, with
C-statistics of 0.82 for death in hospital and 0.70 for
death or myocardial infarction in hospital (table 1).
Nine factors independently predicted death and the
combined end point in the period from admission to
six months after discharge: age, congestive heart
failure, peripheral vascular disease, systolic blood pres-
sure, Killip class, initial serum creatinine concentration,
positive initial cardiac markers, cardiac arrest on
admission, and number of leads with ST deviation. The
highest hazard ratio for adverse outcome was for
cardiac arrest (table 1).
Prospective and external validation of the GRACE
risk score
When we tested the risk model in the prospective vali-
dation set, it had excellent predictive accuracy for
death and death or myocardial infarction. The predic-
tive accuracy was maintained across the acute coronary
syndrome subgroups (table 2).
We validated the model externally using the
GUSTO IIb dataset of 12 142 patients with acute coro-
nary syndrome. There was excellent discrimination
despite the fact that one of the key parameters was not
recorded in GUSTO IIb (cardiac arrest). The C-statistic
for the death model in all patients was 0.82
(C-statistics = 0.80 for ST segment elevation myocar-
dial infarction and 0.76 for non-ST segment elevation
myocardial infarction).
Development of a simplified nomogram for clinical
application
We reduced the overall models to include the most
important variables that contained most ( > 90%) of
the predictive information. This nomogram retained
excellent discriminant characteristics based on eight
variables and was used for the calculation of risk
(fig 2).
Discussion
The GRACE risk prediction tool (simplified nomo-
gram) includes variables that are readily available to
clinicians even in smaller community hospitals. It pro-
vides a novel and widely applicable method of assess-
ing the cumulative six month risk of death and death
or myocardial infarction across the spectrum of
patients admitted to hospital with acute coronary
syndrome.
The need for risk prediction in patients with acute
coronary syndrome
In clinical practice, initial stratification of patients aims
to identify those suitable for reperfusion therapy (on
the basis of a clinical syndrome and ST segment eleva-
tion or other electrocardiographic markers of acute
infarction). There is a need for one predictive
instrument that performs well in all patients with acute
coronary syndrome.
Evidence and practice guidelines suggest that
interventional and pharmacological therapies pre-
dominantly benefit patients at higher risk.2 8 9 Identifi-
cation of patients at high risk of cardiac ischaemic
events, however, remains challenging.10 11 In addition,
the triage of patients into high intensity care units (car-
diac care units) is based predominantly on the criteria
for reperfusion therapy rather than risk in the patient.
How does the present model differ from previous
methods of risk stratification?
Several other multivariable prognostic models have
been developed, most of which were derived from
Table 2 C-statistics for validation of the full model and the
simplified model (as used for the nomogram) for all GRACE
patients and for acute coronary syndrome subgroups
All patients STEMI Unstable angina/
NSTEMI
All GRACE patients
Death:
Full model 0.82 0.82 0.81
Simplified model 0.81 0.82 0.79
Death or myocardial infarction:
Full model 0.70 0.66 0.71
Simplified model 0.70 0.66 0.70
Transferred patients
Death:
Full model 0.83 — —
Simplified model 0.83 — —
Death or myocardial infarction:
Full model 0.71 — —
Simplified model 0.70 — —
Model validation*
Death:
Full model 0.82 0.83 0.81
Simplified model 0.81 0.82 0.81
Death or myocardial infarction:
Full model 0.73 0.73 0.73
Simplified model 0.73 0.73 0.73
STEMI=ST segment elevation myocardial infarction; NSTEMI=non-ST segment
elevation myocardial infarction.
*On subsequent patients with acute coronary syndrome (22 122 enrolled
between 1 October 2003 and 30 September 2005).
Age Years Cardiac arrest at admission
At Admission (in-hospital/to 6 months) At Discharge (to 6 months)
ACS  Risk  Model
HR bpm
SBP mmHg
Creat. µmol/l
CHF Killip Class
US Units
Calculator Instructions GRACE Info References Disclaimer
Reset
ST-segment deviation
Elevated cardiac enzymes/markers
Probability of
In-hospital --
To 6 months
Death Death or MI
--
--
--
Fig 2 GRACE risk calculator for death or myocardial infarction from
admission to hospital to six months after discharge with the
simplified model (www.outcomes.org/grace)
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clinical trial databases or specific subgroups of patients
with acute coronary syndrome. Patients with complica-
tions and comorbidity tend to be excluded from such
trials, thus limiting applicability. Models developed
from large claims databases are potentially subject to
bias. In contrast, the GRACE registry spans the
spectrum of acute coronary syndrome and is based on
an unselected contemporary population.
An independent study suggests that the unselected
GRACE mortality model is superior to either the TIMI
(thrombolysis in myocardial infarction) or the PUR-
SUIT (platelet glycoprotein IIb/IIIa in unstable angina:
receptor suppression with eptifibatide) models.12 We
have shown that the cumulative (0 to six month)
GRACE risk model performs well across the spectrum
of acute coronary syndrome and has prospective and
external validity.
Simplified risk calculation for clinical application
The simplified model includes most of the predictive
information: > 92% of the total model 2 for death and
> 90% for death or myocardial infarction (fig 2). The
GRACE risk calculator (available at www.outcomes.
org/grace) can be used to derive a prognostic score
and to estimate the risk of death or the combined risk
of death or myocardial infarction in individual patients.
This nomogram can be installed into a handheld
device or personal computer (data entry takes about 30
seconds) and is also available as a score card.4
Limitations
GRACE is designed to enrol an unselected and gener-
alisable population of patients, though some partici-
pating centres are required to obtain informed consent
from patients before enrolment. Therefore some
patients who died early or who experienced major
clinical complications immediately on arrival in hospi-
tal may be under-represented. The model may not be
appropriate for stratifying low risk patients with
non-specific chest pain without acute coronary
syndrome, but such patients do not require the same
therapeutic and management decisions as those with
acute coronary syndrome.
We thank the physicians and nurses who participated in
GRACE. The risk calculator is available together with further
information about the project and the complete list of
participants from www.outcomes.org/grace. We thank Sophie
Rushton-Smith for editorial services.
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What is already known on this topic
Specific treatments are indicated in higher or
lower risk patients with acute coronary syndrome
Conventional clinical assessment and binary
methods for predicting risk based on results of
electrocardiography and markers of injury are not
sufficiently accurate
Previous risk models were based on subgroups of
patients with acute coronary syndrome and were
derived from large clinical trials or healthcare
claims databases
What this study adds
The GRACE risk tool can be used to predict the
cumulative risk of death and death or myocardial
infarction in the period from admission to
hospital to six months after discharge
The tool is simple to apply, robust, externally
validated, and applicable to patients across the
complete spectrum of acute coronary syndrome
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